I was absolutely against being distracted from our goal to get the bacteria N-Assays to market until I realized how bad COVID-19 is. I remembered how ebola was almost a non-event in hind-sight and thought this coronavirus would run the same. But it hasn't. It became the thing I thought ebola was going to be.

Then I found out that all the ingredients needed to configure the N-Assay for the coronavirus were readily available and in stock and countries like Singapore was using ELISA to detect for antibodies. Finally, it dawned on me that all we needed was an entity like the CDC to slap it together in a couple days and confirm it works (which we know it does as it did with ebola).

Scott is right. All the Company needs to do is license the patented technology and it would take minimal effort to do that since there isn't any corporate red tape to get thru -- as you said, the CEO does everything.

If no one comes calling, then so be it and we continue onward as the Company stated in the last update. But I think the Company should pursue any potential lead as long as it doesn't take capital resources away from our N-Assay goals.